Pharmacy Times

JUNE 23, 2025

The hospitals and the payment plans would not use your generic drug if you weren’t therapeutically equivalent—we would exclude you,” Soefje said. Historically, CMS would stack all multisource generic 505(b)(2) drugs under the same J-code, Soefje explained. That has changed based upon the [recent] CMS ruling.”

Pharmacy Technician

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Pharmacy Technician

Pharmacy Times

JUNE 12, 2025

Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted.

Biosimilars

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process.

Pharmacy Technician

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

Inpatient

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy.

Pharmacy Technician

Pharmacy Times

JULY 23, 2025

Pharmacy Times : Despite no difference in ED visits or hospitalizations, the reduction in urgent clinic visits was significant—how do you interpret that outcome? Przespolewski : When you look at the interventions around avoiding ER visits or hospitalizations and see no difference in the data, it can seem like a negative.

Pharmacy Technician

Pharmacy Times

JUNE 20, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 9, 2025

For example, CPAs are especially impactful in managing chronic conditions such as diabetes, heart failure, and rheumatoid arthritis, where pharmacist intervention has been shown to improve outcomes and reduce hospitalizations. Subscribe Now!

Pharmacy Technician

Pharmacy Times

JUNE 10, 2025

The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals.

Pharmacy Technician

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage

Pharmacy Times

JUNE 19, 2025

Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

Pharmacy Technician

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.

Pharmacy Technician

Pharmacy Times

JUNE 9, 2025

SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. 1,2 Nivolumab and chemotherapy is a standard of care option for resectable non-small cell lung cancer.

Chemotherapy

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Pharmacy Technician

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy

Pharmacy Times

JULY 3, 2025

In most hospitals, you have what's called “meds to beds,” where the outpatient pharmacy will fill the discharge prescriptions and bring them to the floor. So making sure the right medicines are coming from where they need to be and that it’s not hard for the nurse to get them. Well, this is an outpatient unit.

Inpatient

Pharmacy Times

JUNE 9, 2025

At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.

Pharmacy Technician

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. For both trials, the major efficacy outcomes were confirmed overall response rate (cORR) and duration of response (DOR).

Pharmacy Technician

STAT

JULY 16, 2025

Cancer weakens the immune system, and common therapies on which we rely, such as chemotherapy, further diminish the body’s ability to protect itself from infections. An upper respiratory infection might be an inconvenience for a healthy adult. For an immunocompromised person living with cancer, it could be fatal.

Chemotherapy

Pharmaceutical Technology

JULY 1, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up for our daily news round-up!

Packaging

Pharmacy Times

JUNE 18, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Pharmacy Technician

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!

Biosimilars

Pharmacy Times

JUNE 25, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Pharmacy Technician

Pharmaceutical Technology

JULY 1, 2025

In June 2025, the European Commission authorised Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate, combined with chemotherapy for treating adults who are newly diagnosed with Stage IIb Hodgkin’s lymphoma with risk factors or at Stage III/IV. Sign up for our daily news round-up!

Packaging

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

Pharmacy Technician

Express Pharma

DECEMBER 19, 2024

Antibiotics have long been essential in treating common infections and supporting complex medical interventions like surgeries, cancer chemotherapy, and organ transplants. However, the misuse and overuse of these critical drugs have catalysed a global health crisis: antimicrobial resistance (AMR).

Pharmaceutical Companies

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy

Beckers Hospital Review

JULY 28, 2025

These drugs make a huge difference in outcomes for patients, but they are not as familiar with the concept as they are with chemotherapy. The post Diagnostics, AI, access: Cancer care areas ripe for innovation, per 6 leaders appeared first on Becker's Hospital Review | Healthcare News & Analysis. Additionally, immunotherapy.

Medical Schools

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Biosimilars

Pharmacy Times

JUNE 6, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 18, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmaceutical Technology

JULY 7, 2025

Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated. Give your business an edge with our leading industry insights.

Labelling

Pharmaceutical Technology

JULY 4, 2025

Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024.

Chemotherapy

Pharmacy Times

JUNE 17, 2025

This entails an increased risk of developing secondary diseases, such as type 2 diabetes and cardiovascular diseases,” Wile Balkhed, PhD student at Linköping University and resident physician at Linköping University Hospital, said in a news release. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Diabetes